Get the Stockscreener App
0.95
2.68%
-0.0262
Rallybio Corp stock is traded at $0.95, with a volume of 104.01K.
It is down -2.68% in the last 24 hours and down -4.44% over the past month.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$0.9762
Open:
$0.97
24h Volume:
104.01K
Relative Volume:
1.31
Market Cap:
$39.41M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.4868
EPS:
-1.9516
Net Cash Flow:
$-60.27M
1W Performance:
-12.04%
1M Performance:
-4.44%
6M Performance:
-34.03%
1Y Performance:
-65.45%
1-Day Range:
$0.9315
$1.00
1-Week Range:
$0.93
$1.0807
52-Week Range:
$0.93
$3.46
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.95 | 39.41M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio stock plunges to 52-week low, touches $0.94 - Investing.com
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase - Investing.com
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase By Investing.com - Investing.com UK
US Penny Stocks To Consider In December 2024 - Simply Wall St
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio Corporation Announces Promising RLYB212 and RLYB332 Preclinical Data at 66th American Society of Hematology Annual Meeting - Marketscreener.com
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66 - Business Wire
Rallybio's ASH Data Shows Breakthrough Potential in Blood Disorder Treatments, Strong Preclinical Results - StockTitan
Rallybio price target lowered to $7 from $8 at JMP Securities - Yahoo Finance
Rallybio (NASDAQ:RLYB) Earns Buy Rating from HC Wainwright - Defense World
Rallybio shares retains Buy rating on treatment potential By Investing.com - Investing.com Australia
Rallybio shares retains Buy rating on treatment potential - Investing.com
Rallybio : RLYB116 Clinical Program Update – Harnessing the Power of C5 Inhibition - Marketscreener.com
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 - Business Wire
Rallybio advances Phase 2 trial for rare pregnancy condition By Investing.com - Investing.com Nigeria
Rallybio Flat On Release Of New Findings - MENAFN.COM
Rallybio Flat on Release of New Findings - Baystreet.ca
Rallybio advances Phase 2 trial for rare pregnancy condition - Investing.com
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women - Business Wire
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.01% - MSN
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference - Marketscreener.com
Rallybio's SWOT analysis: rare disease biotech stock advances FNAIT treatment - Investing.com
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor - Business Wire
Rallybio to Host Key Webcast on RLYB116 C5 Inhibitor Development Updates - StockTitan
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women - Clinical Trials Arena
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 - Business Wire
Rallybio Launches Phase 2 Trial for Groundbreaking Pregnancy Treatment RLYB212 - StockTitan
Rallybio stock hits 52-week low at $0.96 amid market challenges - Investing.com India
FMR LLC Acquires Shares in Rallybio Corp - GuruFocus.com
HC Wainwright Issues Pessimistic Forecast for Rallybio (NASDAQ:RLYB) Stock Price - Defense World
Staff cuts help New Haven-based biotech Rallybio reduce 3Q loss - Hartford Business Journal
Rallybio Co. (NASDAQ:RLYB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - BioSpace
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech - PharmaVoice
Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada
Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada
Rallybio advances novel FNAIT prevention trial - Investing.com India
Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks
Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):